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Defining topological similarities among ion transport proteins with
anti-amiloride antibodies. The structural features of amiloride binding
sites on amiloride-sensitive transport proteins have received limited
characterization. An antibody that recognizes limited regions of amiloride
and can mimic, in binding specificity, certain amiloride-sensitive transport
proteins was used as a model to elucidate potential amino acid residue
relationships that might define putative amiloride contact sites. Analysis of
the structure of this antibody has allowed us to identify sequence
relationships among several Na selective transport proteins. A structure-
based relational database was employed to re-examine sequence homol-
ogies among these ion transport proteins. A search of the protein
sequence databank identified representative amino acid tracts among
amiloride sensitive proteins involving planar residues that might be
involved in interacting with amiloride. Computer models of sites within
transmembrane domains of NHEI and NHE2 isoforms of the Na/H
exchanger reflective of these planar tracts indicate that amiloride probably
spans two helices for interaction with the Nat'H exchanger. Structural
analysis of this monoclonal anti-amiloride antibody appears to mimic
some of the salient features of amiloride binding sites on these proteins.
The diuretic amiloride and its derivatives have proved to be
effective inhibitors of a large number of membrane transport
processes. These compounds have been used to discriminate
various Na transport systems including epithelial Na4 channels,
eukaiyotic Na/H exchangers (NHE5), Na/Ca2 exchangers,
and Na-hexose cotransporters [1—4]. The cascade of biologic
effects influenced by ion transport inhibition range from control-
ling enzyme activity affecting cell cycle and growth, to prolifera-
tion and differentiation that lends to malignant transformation. In
addition to its therapeutic application as a diuretic, amiloride has
shown utility in the treatment of cystic fibrosis [5], and compounds
based upon amiloride that specifically block ion transport proteins
might also have therapeutic value in cancer treatment [6—91.
Amiloride and its analogs have also been shown to interact with
specific drug and hormone receptors and inhibit cellular metab-
olism and DNA, RNA and protein synthesis [11. The development
of new, selective transport inhibitors would be greatly enhanced
by understanding the structural organization of binding sites on
proteins that interact with amiloride or amiloride analogs.
Amiloride is pyrazinoylguandine, bearing amino groups on the
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3- and 5-positions and a chloro group on the 6-position of the
pyrazine ring (Fig. 1). Numerous analogs have been synthesized
and representative members clearly show that appropriate modi-
fications of the structure of amiloride will generate analogs with
increased affinity and specificity for a particular transport system.
Introduction of hydrophobic substituents on the terminal nitrogen
of the guanidinium moiety enhances activity against the Na
channel (H-type), whereas addition of hydrophobic (or hydro-
philic) groups on the 5-amino moiety enhances activity against the
NHE1 isoform of the Na/H exchanger [10—12]. Activity against
the Na/Ca2 exchanger and Ca2 channel is increased with alkyl
substituents at either of these sites.
Structural features of amiloride binding site(s) on amiloride-
sensitive transport proteins have received limited characteriza-
tion. Studies using amino acid specific reagents suggest that Tyr
and His residues participate in the binding of amiloride (or Nat)
to the Na channel, Na/H exchanger, and Na glucose co-
transporter [13—18]. Site directed mutagenesis of specific His
residues of the Na/H exchanger (NHE1 isoform) alters amilo-
ride sensitivity, providing additional evidence for the role of His
residues in amiloride binding [19]. The development and analysis
of amiloride insensitive mutants of the Nat'H exchanger, and
the analysis of site directed mutants of NHEs, led to the identi-
fication of amino acid residues (Leu and Phe) which participate in
amiloride binding to NHE1 and NHE2 isoforms of the Na/H
exchanger [20—22], confirming the role played by planar and
hydrophobic residues in amiloride binding. The interactions of
amiloride with amino acid residues on transport proteins might be
reflected in the binding of amiloride to nonmembrane associated
amiloride sensitive proteins. The folding of these proteins could
result in amiloride contact residues being similar in three-dimen-
sions that are otherwise cryptic in linear sequence alignments.
Antibodies have been developed that recognize limited regions
of amiloride and can mimic, in binding specificity, certain amilo-
ride-sensitive transport proteins [23, 24]. These antibodies serve
as a model system to identify structural features required for
amiloride binding and provide a framework for predicting puta-
tive structural characteristics of amiloride sensitive transport
proteins. The hypothesis that an antigen binding site on an
anti-ligand antibody may mimic a receptor (or binding site) for
that ligand has received experimental support from numerous
studies [reviewed in 25]. The extent of sequence homology
between antibodies and receptors may be limited to small regions
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Fig. 1. Schematic of amiloride and 5-(N-methyl-N-propyl)amiloride (MPA)
structures.
which are critical for ligand binding. This has been clearly
demonstrated in a variety of systems, and is best represented
within the framework of polypeptide ligands for specific receptors,
and anti-receptor antibodies raised by an antiidiotypic approach.
In seven systems examined (such as thyroid stimulating hormone
[26], fibrinogen [27], reovirus type 3 [281, hepatitis B [29], mouse
mammary tumor virus glycoprotein gp52 [30], carcinoembryonic
antigen (CEA) [31], granulocyte/macrophage colony stimulating
factor (GM-CSF) (Williams, W.V. and T. Kieber-Emmons, un-
published observations), limited, yet significant homologies
among the ligands and anti-receptor antibodies were observed.
Moreover, these homologous regions were within the domains on
the ligands thought to directly participate in receptor binding, and
were within domains of antibody hypervariable regions predicted
to participate in antigen (such as receptor) binding. Recent
structural analyses of antibodies that mimic the adhesion motif
RGD on fibrinogen [27, 32] indicate that the complementary
determining region 3 (CDR3) on the heavy chains adopts confor-
mations that are displayed by highly constrained bioactive RGD
containing peptides [33].
We have recently reported the structural analysis of a mono-
clonal antibody (mAb) directed against amiloride [34]. MAb
BA7.1 mimics the epithelial Na channel in binding specificity of
amiloride derivatives [23]. The variable regions of the heavy and
light chains of mAb BA7.1 were sequenced [34] and the deduced
II
amino acid sequence is illustrated in Figure 2, highlighting those
residues that contact amiloride. The heavy chain is encoded by a
VH gene of the J558 gene family, an FL16 D gene segment, and
a JH4 gene. The light chain is encoded by a member of the Vk19
subgroup and a Jk2 gene. To dissect potential interactions be-
NH2 tween amiloride and amiloride-sensitive transport proteins, a
tertiary structural model of BA7.1 was constructed from its
primary sequence (Fig. 3). The model indicates that planar amino
acids play a prominent role in stabilizing the interaction of
amiloride with the antibody, forming a pocket into which amilo-
ride inserts [34].
Our model of the antigen binding site correlates with the
specificity of binding of amiloride analogs to mAb BA7.1, and
emphasizes the prominent role played by planar amino acids in
stabilizing the interaction of amiloride with the antibody. Princi-
pal contact residues for amiloride are located on both the heavy
and light chains of BA7.1. The antibody combining pocket is
surrounded by Tyr or Phe residues located in the CDR3 domain
of both the light (L) and heavy (H) chain. The Cl atom on
amiloride is stabilized by an electrostatic interaction with the His
residue at position 104 of the H chain. The 5-amino group of
amiloride is stabilized by hydrogen bonding and/or electrostatic
interactions with the backbone carbonyl of Gly L89 and the
hydroxyl group of Ser L34. The pyrazine ring exhibits stacking
interactions with Tyr L96, and the guanidinium moiety has
stacking interactions with Tyr L94. The carbonyl moiety hydrogen
bonds with the backbone amide of Tyr L94. While the three-
amino group is not involved in hydrogen bonding to mAb BA7.1,
this group appears to be stabilized by stacking interactions with
Tyr L96 and perhaps by polarization affects. These putative
contact residues are similar to those suggested to affect amiloride
binding in amiloride-sensitive proteins, as discussed above, and
indicates that mAb BA7.1 mimics some of the salient features of
their amiloride binding site(s).
Potential ligand contact residues among several amiloride-
sensitive proteins were identified by considering the interaction of
amiloride with mAb BA7.l. A limited sequence relationship
between the CDR3 region of BA7.1 H chain and several Na
transport proteins, including one of the subunits of the epithelial
Na channel (arENaC) [35], and a tract within the fourth
membrane spanning domain of NHE isoforms shown to be
associated with amiloride binding by site directed mutagenesis
studies [21]. These relationships allow for reconsideration of
sequence alignments among various amiloride-sensitive proteins
and other Na-selective transport proteins in an effort to specu-
late about the organization of amiloride binding sites on these
proteins.
Results
To examine the local structural fold of regions of interest,
secondary structure predictions were performed using the PEP-
TIDESTRUCTURE program in the GCG software package
version 7.1 [36]. Further analyses of topological relationships were
performed by examining crystallographically known structures
using the IDITIS version 2.0 (Oxford Molecular Ltd.) relational
database and by molecular model building. In the IDITIS search,
secondary structure assignments are one letter summaries of the
hydrogen bonding structure patterns in which the residue is
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involved. We have used the extended Kabsch and Sander algo-
rithm implemented in IDITIS. The extended search accounts for
the secondary structure of the flanking residues, with assignments
of all residues that form the terminus of their element secondary
structure assigned the one letter code of that element. To develop
possible models of local regions we compared patterns of se-
quences found in the crystallographic database. The theoretical
basis of this method is the assumption that the secondary structure
tendencies of a protein are implicit in the alignment of primary
sequences of proteins that have defined structural motifs. The
most probable secondary structure of a local region is chosen from
a library of known super-secondary structures. This method
ultimately permits a three-dimensional structure to be inferred
from primary sequence.
The analysis of the topologic organization of amiloride contact
residues within mAb BA7.1 indicates that these residues are
located in turn regions within CDRs, with planar amino acid
residues defining the residue environment for contact. The Gly
and His residues within the H chain CDR3 domain define a turn
region, that along with planar residues, lend to stabilizing amilo-
ride. Subsequently, the putative tract YYOHYT at the tip of the
H chain CDR3 region describes a structural environment that
might define a putative amiloride binding site. A putative turn has
been described by Deguchi, Yamato and Anraku [37] that in-
cludes a common motif purported to describe a topological
domain that involves Na recognition or binding that has been
identified within the Na coupled glucose, proline, and glutamate
cotransporters (Fig. 4). An equivalent motif has been postulated
Fig. 2. Deduced amino acid sequences of the
variable regions of the heavy and light chains of
the monoclonal anti-amiloride antibody BA 7.1.
Single letter amino acid code is listed. Residues
which are predicted to form the hydrnphnbic
pocket for amiloride binding or contact
amiloride directly are in bold print. The
putative contact residue in the heavy chain is
position 104 (H). The putative contact residues
in the light chain arc at positions 34 (5), 89
(G), 94 (Y) and 96 (Y). The CDR regions are
underlined sequentially (CDR1-CDR3) for both
chains.
in a Na/PO42 cotransporter which contains a PR tract at the
analogous OR position (Fig. 4) [38].
The IDITIS database was probed in order to examine the range
of conformational properties available to OH and OR residues.
The results indicate that OR and OH residues can be located in
turn regions, displaying both similar and varying conformational
properties for flanking residues (Table 1). The queries indicate
that the structural features preceding the putative turn display
helical, extended, beuds and turns. In some cases the same
sequences exhibit differing conformations. This is the result of
differing degrees of crystal structure resolution as well as the affect
of differing influences of the tertiary environment on the local
secondary structure. In Table 1 the tract LAORQE (2YHX) is
most similar to that observed for the CDR3 domain of BA7.1. The
LAOR tract is similar to the LAPR tract observed in the
Na!PO42 transporter (Fig. 4). Representative tracts in Table 1
for the other transport proteins in Figure 4 are AGOR (2WGC),
identical to the AGOR tract observed in the Nat/glutamate
cotransporter and AWOOR (6XIA), similar to the VWVOR tract
observed in the Nat/proline cotransporter.
To further explore the structural properties of residue environ-
ments that might be shared among amiloride-sensitive protein
sequences, the crystallographic database was probed with the
motif subset Y-X-X-Y or planar residue -X-X- planar residue,
where X is any residue, and planar residues include Tyr, Phe and
Trp. Queries indicated that these motifs are found within turn and
helical secondary structures. Amiloride-sensitive proteins were
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Fig. 3. Molecular model of BA 7.1 interacting with amiloride. The Tyr at position L94 and L96 are colored green and displayed as solid sphere rendering.
Amiloride (stick model) is outlined in white and magenta and is shown stacking on the Tyr residues. Also in solid sphere rendering are His H104 colored
cyan, and Ser L34 colored magenta.
Rabbit NaJPO4
E. coil Na/glutamate
Rabbit Na/glucose
E. coil Na/proline
Na channel (cxrENaC)
ABP
NHE3
BA7.1
then queried for such tracts, with several being identified. Se-
quence queries indicated that the sequence YYGHY contained in
the H CDR3 domain of mAb BA7.1 aligns with the sequence tract
WYRFHY in arENaC, a component of the epithelial Na
channel [34, 35, 39]. The IDITIS database was then queried for
occurrences of the FH diresidue tract to assess its propensity to be
found in turn regions. These analyses indicated that FH residues
can be located in turn regions, displaying conformational proper-
ties (Table 1) similar to GH and GR tracts.
Based upon the tract WYRFHY arENaC, we have identified an
FHYY tract in the protein ABP (Amiloride Binding Protein).
APB was originally isolated by Barbry and co-workers from renal
cortex on the basis of [3H]phenamil binding [40]. This protein was
initially postulated to be a component of the epithelial Na
channel, although injection of ABP cRNA into oocytes did not
PRYYVFIK
GRWGIE'L
GRLFMLF'L
GRVMVLW
RFHYI
FHYY
TTLIVVFF
GHYT
elicit an amiloride-sensitive Na current [41] and subsequent
molecular analysis indicates that this protein is diamine oxidase
[42]. An alignment of arENaC and APB is shown in Figure 5. Also
included in the Figure are predicted consensus secondary struc-
tures for arENaC and APB calculated with the PEPTIDE-
STRUCTURE program. Secondary structure predictions indicate
similarity among these two proteins in the region initially identi-
fied by the homology between BA7.1 and arENaC. Figure 4
illustrates an alignment of arENaC and APB with several Na
selective transport proteins. To a varying extent, each of these
proteins reflect some aspect of the motif originally identified by
Deguchi et al [37]. The role of residues identified by Deguchi et al
[37] in amiloride binding or in Na transport have not been
delineated, although our preliminary studies examining functional
expression of arENaCz278—283 (the tract WYRFHY has been
342 GLLL FIVE' S MCLLYLSSGFY STITFLILANASSSFCLGGALINALDLA
42 GLLVA LALLVLKKSMGWEVNFDMSLP.DPLMLPY FATIGLNANIASLRAG
380 GLMLS VMMPSLMSSLTSI FNSASTLFTMDIYTKIRKK ASEKELMIA
328 GVLLS AILAAVMSTLSCQ LLVCSSAITEDL YKAFLRKH ASQKELVWV
233 GLPAY ATTIPQVDRKDWKIGFQLCNQNKSDCFYQTYSS GVDAV BE WY
359 GGHT PAGMQTKYLDVGWGLGSVTHELAPGID CPETAT LD T
413 GAVA YALVVLL DEKK VKEKNLFVS
FNYY
Fig. 4. Alignment of the Na k-selective transport proteins with the CDR3 region of mAb BA 7.1 heavy chain. Residues in bold type parallel those proposed
to define a Na binding domain as proposed by Deguchi et al [371. The number indicates the location of the N-terminal glycine residues within the
sequence of the parent protein.
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Table 1. IDITIS search of putative halide contact region
OR tract Secondary
Brookid Sequence structure
Table 1. Continued
OR tract
Brookid Sequence
Secondary
structure
FH tract (continued)
1YPI ERRSYFHEDDKF HHHHhTL hHHH
2LDX TLVKGFHGIKEE EEeTTSTTt 55
2MEV CNASQFHAGSLL a tTTtEEEEE
2YPI ERRSYFHEDDKF HHHhTTt hHHH
PR tract
1FDL TVPSSPRPSETV EEEeTTTTTL a
1GP1 QRRLGPRGLVVL HHHHhTTeEEEE
1PHH IYANHPRGFALC EEEEETTEEEEE
1PRC EGDVDPRGLPVV TTt tTTeEEE
1R69 GKTKRPRFLPEL Tt SSLThHHHH
2CD4 VQCRSPRGKNIQ EEEEeTTteEEE
2CRO GVTKRPRFLFEI Tt SStTI-XHHHH
6XIA FDFKPPRTEDFD Ee tTTLhBB
7CAT SLTVGPRGPLLV BSLTTt BST
155C
1C2R
lccP
1CCR
ICN1
1CSC
1DRE
IFCB
box
1GPD
1HNE
1HNE
1LAP
1LYM
1PFK
1PRC
1R08
1TEC
1UBQ
1WOC
1YcC
2ATC
2CAB
2CCP
2FB4
2FBP
2HLA
2PFK
2SOD
2WOC
2WGC
2YHX
3CYT
3FBP
3GRS
3XJA
4FAB
SACN
5ADH
5CSC
5XIA
6DFR
6XIA
1ALD
1AZU
icox
1CTX
lop'
IHDS
1MBC
1RUS
2AZA
2HFL
2PAZ
2RUS
2TS1
3APP
3B5C
3ENL
3XIA
4T51
4XIA
PH tract
1PHH
IPYP
bROS
1R1A
LYGVVGRKIASE
LYGVVGRTAGTY
ASVEKGRSYEDF
LNGLFGRQSGTT
PSGSTSRLLGLF
NTLNSGRVVPGY
NRPLKGRINLVL
LSNHGGRQLDFS
VKAAQGRIPVFL
GINGFGBIGRLV
QLPAQGRRLGNG
CTLVRGRQAGVC
RKGMAGRPTRTL
• . KVFGRCELAA.
VVEVMGRYCGDL
PASRLGRQGEAP
PYTS IGRTNYPK
LLASQGRSASNI
KQJJEDGRTLSDY
GKDAGCRVCTNN
LHGIFCRHSSQA
GDLKYGRTVHSL
TQPLKGRTVRAS
ASVEKGRSYEDF
GVVQPGRSLRLS
DALQPGBNLVAA
SVSRPGRGEPRF
VVEVBGRYCGDL
KPDDLGRGGNEE
GKDAGGRVCTNN
GKDAGGRVCTNN
LISLAGRQES SI
LWGLFGRKTGQA
DALQPGRNLVAA
VTAVPGRLPVNT
TVCWQGRDPFGD
GLVQPGRPMXLS
NBNFTGRNDANP
MLLLSGRTW}CGA
NTLNSGRVVPGY
FVBWGGREGSEY
GRPLPGRKNIIL
YVAWGGREGAES
NNVTPGHACTQK
FCTFPGHSALMK
SBKAQGHLPNLS
KDCPNGI-IVCYTK
PCNQFGBQENAK
LTKAQGBLNDLP
I LKKKGHHEAEL
GGGAFGHIDGPV
FCSFPGHWMSMK
VKQRPGI-tGLEWI
IPVDKGHNVESI
CGGAFGHIDGPV
RFQQAGHRPIAL
ASQQSGHSVYNP
NFEDVCHSTDAR
AIKAAGHuGKVK
LLPTVGHALAFI
RFQQAGHRPIAL
QDLVFGHGDLTS
AGCDGFHGISEQ
KPVSAFHDIPLY
CNATKFHSGCLL
CNASKFHQGTLL
eSStTTttTTtS
CTTtTTtBTTtL
LTTthHHHH
LTTSTTtBTTtC
CTTttTTTTTTL
HHFiHhTt tTTE
GgStTTtEEEEE
EetTTTTLLTTt
HHHhTTtSeEE
EEEeSCThHHHH
tTTt tTT
EEECTTL B S
SEEeSThHHHH
B LThHHBB
EEEE STTLhHH
gGGGgSTTS
LTTS S
HHHhTTtIIHHHH
EEeLTTLBgGGG
GGGGgTSgGGG
LTTSTTSBTTtL
S SSSThHHHH
tTTS eEEe
a STTL11HHHH
eEESTTSEEEE
GOg STTLeEE
EEetTTSS EE
EEEESSTTShHH
S STTSSSSTT
gGGGgTS tTT
STTTTTS gGGG
EEEEETTEEEEE
STTSTTSBTTSS
TTTLLTTL SEE
EEeSTTS EEE
STTTTSS
STTS eEEE
S STTTTTSST
uHHHhTSEEEEe
HHHHhTS LTTB
BEE LTTeEESt
hS STTSeEEEE
EEE STTeEBSg
STTS S
Ee STTTTTTeE
HHHHhTSSTTSL
STTS EEEE
EeLTTTTS Sg
HHHHhSSTTIIHH
HHhTTTLhHHI-W
eTTTTTLTThHH
Eu STTSTTTeE
EEEeTTSeEEEE
EEeSTTS BEe
eTTTTSSTThI-tH
HHHHI1TSEEEEE
HHHHhTS BhH
HHHBhTSIIHHHH
HHHH11TSTTTSE
SS SThBHBH
HHHHhTSEEEEE
BSTTSSIIHHH
EEe STTSSgGG
SB tTTTS 55
a tTTSEEEEE
a LTTS eEEE
Secondary structure properties of sequence tracts which contain OR,
OH, PH and PR residues. The IDITIS relational database was searched
for structures containing these residues. Brookid corresponds to the
crystal structure Id; Nomenclature for secondary structure is: H, alpha
helix; E, extended beta; 0, 3/10 helix; P, pi helix; T, turn; B, bridge; S bend,
space coil. Lower case letter depicts beginning or end of respective
structure.
deleted) suggest that this tract has a role in the binding of
amiloride to csrENaC [43].
Discussion
We have utilized an anti-amiloride antibody as a surrogate for
amiloride-sensitive Na transport proteins in order to identify
topologic features of their amiloride binding site(s). Analysis of
the structure of mAb BA7.1 (Figs. 2 and 3) has allowed us to
identify sequence relationships among several Na selective
transport proteins. Our molecular model of BA7.1 emphasizes the
potential role of planar residues in stabilizing the pyrazine ring.
Searching the Swissprot database we have found representative
tracts such as F-X-x-F, or F-x-Y in amiloride-sensitive proteins
(such as ABP, arENaC, and NHE1) that are rare in immunoglob-
ulin CDR sequences.
Anti-amiloride antibodies were not expected to exhibit exten-
sive primary sequence homology with amiloride sensitive trans-
port proteins, as these transport proteins do not share extended
sequence homologies among themselves. The most salient feature
of ligand binding sites on receptor proteins are the residues that
contact the ligand [28, 44]. Among the various proteins that bind
amiloride, it is conceivable that these contact residues are con-
served to some extent. A subset of Na coupled solute transport-
ers, including those that transport P042, glucose, proline, and-
glutamate, do have a common motif, 0
x-ci-R, (were x is any residue and the elongated dash is
tantamount to 37 to 40 residues in length) which has been
postulated to participate in Na transport [37]. Since the cation
coupling mechanism is common to these four carriers, these
conserved amino acids could be essential for Na recognition or
Na binding. However there is no direct evidence that this
domain participates in cation binding. Based upon topologic
features we have extended this potential fold to several other Na
binding proteins (Fig. 4).
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BA7.1 FNYY-GHYT
arENaC GLPAYATTIPQVDRKDWKIGFQLCNQNKSDCFYQTY-sSGvDAVREWYRFHYI
cLrENaC—2ndStr. "•'•'HHTTTTTT••''TTTT•••TTTTBBBBBTTTHHHHHHHTTTT•B
ABP GGHTPAGMQTKYLDVGWGLGSVTHELAPGI DCPE--TATFLDT -FHYY
ABPSS—2ndStr. TT'•TTBBBBBBBTTT••••••••••TTT T'TT--HHHHHHT—TTTT
Fig. 5. Primaiy sequence alignments of BA 7.1, arENaC and APB. Conserved residues are indicated in bold type. Dashes (—) indicate insertions in ABP
relative to urENaC. Consensus of secondary structural (2nd S tr.) predictions were determined by the methods of Chou and Fasman, and Gamier in
the Wisconsin GCG package PEPTIDESTRUCTURE. T indicates a turn region, H indicates a helical structure, B indicates a beta strand, and dots
indicate secondary structures which are indeterminate.
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The model of BA7. 1 emphasizes the role played by planar
residues in stabilizing amiloride. Many amiloride sensitive pro-
teins exhibit high helical content as expected for transmembrane
proteins. Secondary structure calculations indicate that the poten-
tial sequence tract involving planar-planar-X-planar, planar-X-X-
planar, or planar-X-planar can occur in helices as well as in turn
regions, as verified by a search of the IDITIS relational database.
Binding sites for amiloride might well be associated with helical
domains or turn regions. It is possible that motifs involving this
type of tract will ultimately prove to be putative sites associated
with amiloride binding, as suggested in recent studies of the
Na/H4 exchanger isoforms NHE1 and NHE2 [21, 22], where a
sequence tract FFLF was implicated as a potential amiloride
binding site.
Recently, the subset tracts '64VFFLFLLPPI173 and 140VFFLY-
LLPPI149 found in the purported fourth transmembrane domains
of NHE1 and NHE2, respectively, have been implicated to bind to
the amiloride analog 5-(N-methyl-N-propyl)amiloride (MPA; Fig.
1) [21, 22]. This tract fits the general planar-X-X-planar motif
defined by BA7.1, but also highlights a possible organization for
this helical domain. The Na1glucose cotransporter binds MPA,
yet differs in its alignment with the fourth transmembrane domain
of NHE isoforms 1 and 2 (Fig. 6). Based upon the alignment in
Figure 6 it is evident that the Nat/glucose cotransporter does not
use the analogous fourth transmembrane domain for the binding
of MPA. It is of interest that the motif hydrophobic-planar-x-
hydrophobic-planar-hydrophobic within the fourth transmem-
brane domain of NHE1 is also observed within the eighth
transmembrane domain of the Nat/glucose cotransporter [45]
Fig. 6. Sequence alignments of the fourth (4th)
putative membrane spanning domains of the rat
Na/H exchanger isoform NHEI [47], rabbit
Na 7H4 exchanger isoform NI-1E2 [48], the
fourth (4th) putative membrane spanning domain
of the rabbit Na 7glucose co-transporter (GTNA)
[45], and the eighth (8th) putative membrane
spanning domain of the rabbit Na 7glucose co-
transporter. The C-terminal portion of the
"Deguchi fold" [37] identified within the eighth
putative transmembrane domain of the Na7
glucose co-transporter is indicated by italics.
The fourth transmembrane domain implicated
in MPA binding in NHE1 is underlined, as is a
structurally related potential amiloride binding
domain within the eighth putative membrane
spanning domain of the Nat/glucose co-
transporter. Common residues within the fourth
membrane spanning domains of these proteins
are indicated in bold.
immediately following the GR turn identified by Deguchi et at
[37] (Fig. 6).
Residues within the Nat/glucose cotransporter which interact
with amiloride have not been identified. Tyr residues are located
at or near the Na binding site of the Nat/glucose co-transporter,
as chemical modification of Tyr residue(s) inhibits the transporter
in a Na protectable manner [18]. A Tyr is observed seven
residues upstream from the conserved Ala in the motif identified
by Deguchi et at [37]. In addition, Phe residues are located 12 and
15 residues downstream from the conserved Ala. The sequence
428LFMLFLIGISI438 within the Nat/glucose cotransporter is
analogous to 164VFFLFLLPPII174 of NHE1 and is observed after
the Deguchi fold region (Fig. 6). Mutagenesis of this putative
transmembrane region within the Nat/glucose cotransporter
would be required to demonstrate its role in amiloride binding or
Na transport.
Site directed mutagenesis of the NHE1 and NHE2 isoforms of
the Nat/H exchanger indicate that residues Leu'67 and Phe'65
are important for MPA binding to NHE1, with Phe165 also
affecting amiloride binding [21, 22]. The sequence 164VFFLFLLP-
P11174 of NHE1 displays a hydrophobic strip on one side of the
helix made up of positions 164, 167 and 170. In Figure 7, a model
of this region is illustrated with potential binding modes for MPA.
We have found that the pyrazine ring of amiloride can stack with
either the Phe residues at positions 166 or 168 and allow the alkyl
groups of MPA to contact Leu167. If the pyrazine ring of amiloride
stacks with Phe165, the alkyl groups of MPA interact with Val'64,
but do not contact Leu'67. Our model suggests MPA does not
NHE1
NHE2
GTNA
GTNA 8thIAGR L F ML F LI G IS IA W VP IV
YFLP L
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Fig. 7. Molecular model of the puiported fourth transmembrane helix of NHEJ interacting with MM. (A) Solid sphere rendering showing the hydrophobic
strip involving Va1164 colored magenta, Leu''7 colored cyan, and Leu'7° colored green. MPA is colored red with the pyrazine ring of MPA stacked on
Phe'66 and its alkyl group interacting with Leu1'7. (B). MPA stacking on PhelôS with the alkyl group of MPA interacting with Val'64 and Leu'67.
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contact Phe and Leu'67 simultaneously. The stacking arrange-
ment would suggest that amiloride (or MPA) probably spans two
helices since there are no other favorable recognition sites for
functional groups on the face of the helix to interact with
substituents on amiloride. The model indicates that one face of
the helix contains potential residues that might affect helical
packing, involving the first hydrophobic residue (VaP64), the
fourth (Leu'67) and the seventh residue (Leu'70). Mutagenesis of
Phe'65 or Leu167 might alter helical packing and secondarily affect
MPA (or amiloride) binding. Hydrophobic strips on one face of
the helix involving Leu, Val, lie, Phe and Met as exhibited by
NHE1, have been shown to be involved in selective helix-helix
interactions [46].
In summary, in spite of the lack of overall sequence and
structural homology among amiloride-sensitive proteins, there are
identifiable small sequence relationships that are shared among
these proteins. These sequences are suggested to be functionally
related by virtue of the ability of these proteins to bind amiloride.
For small molecules such as amiloride, we suggest that antibodies
can mimic the most salient features of ligand binding sites and
provide useful structural information in the elucidation of poten-
tial ligand binding sites on receptor proteins.
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